智通财经APP获悉，康诺亚-B(02162)再涨超3%，截至发稿，涨2.21%，报55.5港元，成交额750.96万港元。
消息面上，康诺亚发布公告根据公告，阿斯利康宣布其已启动一项AZD0901联合卡培他滨联合或不联合rilvegostomig一线治疗Claudin18.2阳性、HER2阴性的晚期/转移性胃癌、胃食管结合部癌或食管腺癌的多中心、随机对照、III期临床研究(CLARITY-Gastric02)，并完成了首例受试者给药。
根据许可协议条款及条件的规限下，上述临床试验完成首例受试者给药已触发相关里程碑付款，总金额为4500万美元。阿斯利康已支付该里程碑款项。公开资料显示，康诺亚和乐普生物合资设立的KYM Biosciences Inc.（KYM，康诺亚拥有70%权益）于2023年2年与阿斯利康订立全球独家许可协议，授权阿斯利康在全球范围开发及商业化CMG901。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.